Mindrank AI Co. Ltd. and Mindrank Therapeutics (Suzhou) New Drug Research have disclosed new Wee1-like protein kinase (Wee1) and/or tyrosine-protein kinase Yes (YES1) inhibitors potentially useful for the treatment of cancer, inflammation and autoimmune diseases.
Voronoi Inc. has disclosed heteroaryl compounds acting as Myt1 kinase (PKMYT1) and/or Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Recurium IP Holdings LLC has patented new Wee1-like protein kinase (Wee1) inhibitors and/or degradation inducers reported to be useful for the treatment of cancer.
Pharmaengine Inc. and Sentinel Oncology Ltd. have synthesized Wee1-like protein kinase (Wee1) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.
Wee1 and PKMYT1 are two kinases involved in DNA damage repair. The former is located in the nucleus and the latter in the endoplasmic reticulum. Several selective inhibitors of Wee1 or PKMYT1 have been tested in the clinical setting as monotherapy or in combination with other drugs.
Acrivon Therapeutics Inc. has identified new pyrimidine carboxamide compounds acting as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer.
Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. has divulged Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of inflammation, infection, cancer and autoimmune disease.
Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. has described Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of inflammation, infection, cancer, and autoimmune disease.
